Editas Medicine's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $12.16 Mil. Editas Medicine's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $24.37 Mil. Editas Medicine's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $349.10 Mil.
Editas Medicine's debt to equity for the quarter that ended in Dec. 2023 was 0.10.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Editas Medicine's Debt-to-Equity or its related term are showing as below:
EDIT'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.03 Med: 0.11 Max: 0.34
Current: 0.11
During the past 11 years, the highest Debt-to-Equity Ratio of Editas Medicine was 0.34. The lowest was -0.03. And the median was 0.11.
Editas Medicine Debt-to-Equity Historical Data
The historical data trend for Editas Medicine's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
Editas Medicine Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
Get a 7-Day Free Trial
|
|
|
0.11 |
0.07 |
0.05 |
0.12 |
0.11 |
|
Editas Medicine Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Debt-to-Equity |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
0.12 |
0.12 |
0.09 |
0.10 |
0.11 |
Competitive Comparison
For the Biotechnology subindustry, Editas Medicine's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Editas Medicine Debt-to-Equity Distribution
For the Biotechnology industry and Healthcare sector, Editas Medicine's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Editas Medicine's Debt-to-Equity falls into.
Editas Medicine Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Editas Medicine's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Editas Medicine's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Editas Medicine (Editas Medicine) Business Description
Traded in Other Exchanges
Address
11 Hurley Street, Cambridge, MA, USA, 02141
Editas Medicine Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Executives
| Bruce Eaton |
officer: EVP, Chief Business Officer |
C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142 |
| Linda Burkly |
officer: EVP, CHIEF SCIENTIFIC OFFICER |
1 MAIN STREET, CAMBRIDGE MA 02142 |
| Baisong Mei |
officer: SVP, CHIEF MEDICAL OFFICER |
C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142 |
| Gilmore Neil O'neill |
director, officer: CEO |
215 FIRST STREET, CAMBRIDGE MA 02142 |
| Erick Lucera |
officer: EVP, CHIEF FINANCIAL OFFICER |
138 THISTLE ROAD, NORTH ANDOVER MA 08145 |
| Michelle Robertson |
officer: Chief Financial Officer |
C/O MOMENTA PHARMACEUTICALS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142 |
| Elliott M. Levy |
director |
C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140 |
| Mark S Shearman |
officer: EVP, Chief Scientific Officer |
C/O APPLIED GENETIC TECHNOLOGIES CORP, 11801 RESEARCH DRIVE, SUITE D, ALACHUA FL 32615 |
| Lisa Anne Michaels |
officer: EVP/Chief Medical Officer |
C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142 |
| Bernadette Connaughton |
director |
C/O VISTERRA, INC., ONE KENDALL SQUARE, #B3301, CAMBRIDGE MA 02139 |
| James C Mullen |
director |
940 WINTER STREET, PERKINELMER, INC LEGAL DEPARTMENT, WALTHAM MA 02451 |
| Emma Reeve |
director |
C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451 |
| Jessica Hopfield |
director |
C/O 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821 |
| Cynthia Collins |
director |
65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878 |
| Meeta Chatterjee |
director |
C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142 |
Editas Medicine (Editas Medicine) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EDIT has been successfully added to your